Thakare R, Soni I, Dasgupta A, Chopra S
Division of Microbiology, CSIR-Central Drug Research Institute, Sector 10, Janakipuram Extension, Sitapur Road, Lucknow - 226031, Uttar Pradesh, India.
Drugs Today (Barc). 2015 Feb;51(2):117-23. doi: 10.1358/dot.2015.51.2.2245645.
Out of a handful of new drugs currently in clinical trials for the treatment of tuberculosis, delamanid, a nitro-dihydro-imidazole derivative, has successfully emerged. Delamanid is a novel mycolic acid biosynthesis inhibitor that is equally potent against drug-sensitive as well as drug-resistant Mycobacterium tuberculosis. One of the strongest points for delamanid is its inability to be metabolized by cytochrome P450 enzymes, making it a promising candidate to be used in combination therapies for the treatment of tuberculosis and HIV. Additionally, it has successfully completed phase II efficacy trials and has received conditional marketing authorization from the European Medicines Agency.
在目前处于结核病治疗临床试验阶段的几种新药中，硝基二氢咪唑衍生物德拉马尼德已成功脱颖而出。德拉马尼德是一种新型的分枝菌酸生物合成抑制剂，对药物敏感型和耐药型结核分枝杆菌均具有同等效力。德拉马尼德的一大优势在于它不会被细胞色素P450酶代谢，这使其成为用于结核病和艾滋病联合治疗的有前景的候选药物。此外，它已成功完成II期疗效试验，并已获得欧洲药品管理局的有条件上市许可。
